Obesity Hypoventilation Syndrome (OHS)
Conditions
Brief summary
This is a randomized, double blind, placebo-controlled, cross-over, phase II, single center efficacy study of AD981 in patients with obesity hypoventilation syndrome documented by polysomnography (PSG) and transcutaneous, overnight measurement of CO2 (PtcCO2).
Interventions
DRUGAD981
Oral administration of AD981 in the morning and before sleep for 14 days
OTHERPlacebo
Oral administration of placebo in the morning and before sleep for 14 days
Sponsors
Istituto Auxologico Italiano
Apnimed Inc.
VIS Ethic Research Srl
University of Florence
STM Pharma PRO srl
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Intervention model description
Patients who meet the eligibility criteria will be randomized equally to receive AD981 or matching placebo. After 14 days of treatment and a washout period, the patients crossover to the other treatment arm for 14 days.
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Be able to understand the nature of the study and sign the informed consent * BMI \> 35 kg/m2 and presence of nocturnal hypoventilation * Previous surgical treatment for OSA is allowed if ≥ 1 year prior to enrollment * If in treatment, CPAP or BPAP or mandibular advancement device or positional therapy intolerance or poor compliance
Exclusion criteria
* Narcolepsy, craniofacial malformation, renal failure, hepatic disease, schizophrenia, schizoaffective disorder or bipolar disorder, cognitive dysfunction, severe neurological disorder, pheochromocytoma, adrenocortical insufficiency, hyperchloremic acidosis. * Respiratory (COPD, ILD, oxygen therapy) or cardiac (Heart Failure, Atrial fibrillation, established severe peripheral arterial disease) disease or hypertension requiring more than 3 medications for control * Cardiomyopathies, heart malformation or structural heart alterations, severe rhythm disorders, established coronary heart disease or other cardiac conditions, which could determine sudden death * Attempted suicide or suicidal ideation * Drugs of abuse or substance use disorder * A significant illness or infection requiring medical treatment in the past 30 days. * Untreated narrow angle glaucoma. * Women who are pregnant or nursing. * Treatment with strong cytochrome P450 3A4 (CYP3A4) inhibitors, or monoamine oxidase inhibitors (MAOI) or linezolid within 14 days of the start of treatment, allergies to sulfonamides. * Diabetes with unstable glucose control in the past 15 days. * \> 500 mg/day of Aspirin * Low sodium or potassium. * Any condition that in the investigator's opinion would present an unreasonable risk to the participant. * History of using oral or nasal devices (such as mandibular advancement devices) for the treatment of OSA may enroll as long as the devices are not used during participation in the study for at least 2 weeks prior to study begin. * History of using devices to affect participant sleeping position for the treatment of OSA, e.g. to discourage supine sleeping position, may enroll as long as the devices are not used during participation in the study. * Use of another investigational agent within 30 days or 5 half-lives, whichever is longer, prior to dosing. * Patient currently receiving: MAOIs, Serotonin and Norepinephrine Reuptake Inhibitors, Norepinephrine Reuptake Inhibitors, Lithium, Tricyclic antidepressants, strong CYP2D6 inhibitors, other strong inhibitors cytochrome P450, thiazides diuretics, benzodiazepines, opioids, drugs with clinically significant cardiac QT-interval prolonging effects, drugs known to lower seizure threshold, amphetamines, antiepileptics, modafinil or armodafinil, beta2 agonists, antipsychotics, pseudoephedrine, phenylephrine, oxymetazoline, drugs for Parkinson's, Alzheimer's, Huntington's, Amyotrophic Lateral Sclerosis, or drugs for other neurodegenerative diseases, more than 500 mg/day of Aspirin or salicylates, sodium Phosphate. * Known hypersensitivity to study drugs
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Nocturnal transcutaneous CO2 pressure (PtcCO2) | From baseline to the last day of treatment (14 days after the start of each treatment period) |
Secondary
| Measure | Time frame |
|---|---|
| Proportion of participants without nocturnal hypoventilation | From baseline to the last day of treatment (14 days after the start of each treatment period) |
| Apnea-Hypopnea Index (AHI) | From baseline to the last day of treatment (14 days after the start of each treatment period) |
Countries
Italy
Outcome results
None listed